CervoMed Inc (CRVO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.56+0.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRVO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 4.0 | 9.7 | 7.1 | 0.0 | — | — | — | — | — | — | — | — | 0.1 | 0.4 | 0.6 |
| Total Revenues | — | 4.0 | 9.7 | 7.1 | 0.0 | — | — | — | — | — | — | — | — | 0.1 | 0.4 | 0.6 |
| Cost of Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.2 | 2.3 |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 | 0.1 | (1.7) |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 21.3 | 21.8 | 18.8 | 8.4 | 1.3 | 8.5 | 9.4 | 6.6 | 5.8 | 5.1 | 7.3 | 3.9 | 2.9 | — | — | — |
| Operating Income | (31.2) | (28.3) | (18.2) | (7.8) | (3.5) | (24.7) | (16.0) | (11.6) | (19.0) | (11.3) | (18.4) | (6.4) | (14.6) | (12.8) | (11.8) | (16.4) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 0.0 | 0.0 | — | — | — | 0.0 | 0.1 | 0.0 | 0.3 | 0.3 | 0.1 | (0.2) | — |
| Interest & Investment Income | 0.8 | 1.3 | 1.9 | 0.2 | 0.1 | — | — | — | — | — | — | — | — | — | — | — |
| Net Interest Expenses | — | — | — | (0.2) | (0.1) | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 0.8 | 1.3 | 1.9 | 5.6 | (2.3) | — | — | — | — | — | — | 0.0 | (2.6) | 9.8 | (4.9) | (6.2) |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.9 |
| EBT, Incl. Unusual Items | — | — | — | — | (15.6) | (24.5) | (15.9) | (11.5) | (18.8) | (2.4) | (18.4) | (6.7) | (17.2) | — | — | — |
| Income Tax Expense | — | — | — | — | 0.0 | (0.4) | (1.7) | 0.3 | (0.4) | (1.1) | (0.4) | 0.0 | (2.8) | 0.0 | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | — | — |
| Net Income | (30.4) | (27.0) | (16.3) | (2.2) | (5.8) | (24.1) | (14.2) | (11.8) | (18.4) | (1.4) | (18.0) | (23.8) | (14.4) | (2.5) | (6.9) | (22.6) |
| Per Share | ||||||||||||||||
| Basic EPS | (2.96) | (2.98) | (2.02) | (0.82) | (11.20) | (12.38) | (0.30) | (1.76) | (8.21) | (3.16) | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — | — | — | — | (29.11) | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 10.2 | 9.0 | 8.1 | 2.7 | 0.5 | — | — | — | 3.2 | 0.8 | — | 18.6 | — | — | — | — |
| Diluted Weighted Avg Shares | — | — | — | — | — | — | — | — | 3.2 | 0.8 | — | 18.6 | 14.3 | 2.6 | 1.1 | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | (3.5) | (24.6) | (15.9) | — | — | — | — | (6.4) | (14.0) | (12.7) | (11.6) | (16.4) |
| EBIT | (31.2) | (28.3) | (18.2) | (7.8) | (3.5) | (24.7) | (16.0) | (11.6) | (19.0) | (11.3) | (18.4) | (6.4) | (14.6) | (12.8) | (11.8) | (16.4) |
| Effective Tax Rate | — | — | — | — | 0.0% | 1.8% | 10.6% | -2.9% | 2.3% | 43.6% | 2.0% | 0.0% | 16.4% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.